Cargando…
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
The clinical benefit in patients with diverse types of metastatic cancers that is observed upon blockade of the PD-1 – PD-L1 interaction has highlighted the importance of this inhibitory axis in the suppression of tumor-specific T cell responses1–9. In spite of the key role of PD-L1 expression by ce...
Autores principales: | Mezzadra, Riccardo, Sun, Chong, Jae, Lucas T., Gomez-Eerland, Raquel, de Vries, Evert, Wu, Wei, Logtenberg, Meike E.W., Slagter, Maarten, Rozeman, Elisa A., Hofland, Ingrid, Broeks, Annegien, Horlings, Hugo M., Wessels, Lodewyk F. A., Blank, Christian U., Xiao, Yanling, Heck, Albert J.R., Borst, Jannie, Brummelkamp, Thijn R., Schumacher, Ton N.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333292/ https://www.ncbi.nlm.nih.gov/pubmed/28813410 http://dx.doi.org/10.1038/nature23669 |
Ejemplares similares
-
CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022) -
Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020) -
CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022) -
Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021) -
Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)